By Karen Roman Sequana Medical said the company now has five medical centers using its alfapump, the first FDA-approved active implantable medical device to treat liver ascites due to cirrhosis. The ...

Leading US liver transplant center completes its first two implantationsMount Sinai Hospital and University of Pennsylvania also complete multiple implantations Dartmouth Hitchcock Medical Center and ...

The US Food and Drug Administration (FDA) has approved Sequana Medical’s alfapump for the treatment of recurrent or refractory ascites due to liver cirrhosis. The agency’s greenlight makes Sequana’s ...

ZURICH--(BUSINESS WIRE)--Sequana Medical, a Swiss-based medical device company, announced today that it has entered into an agreement with Fresenius Medical Care to commercialize its innovative ...

Ghent, Belgium – 06 July 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and ...

Sequana Medical said the first implantation of the alfapump in the U.S. at Mount Sinai Hospital received FDA approval for the treatment of recurrent or refractory ascites due to liver cirrhosis.

One-year alfapump data from POSEIDON shows safety and strong efficacy profile is maintained at 12 months Patient preference study indicates that US patients have a strong preference for the alfapump ...

Untreated umbilical hernias occur in 20% of patients with ascites due to liver cirrhosis. Without treatment, there is a significant risk of complications that are life threatening and require ...

Ghent, Belgium – 23 December 2024 – Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical") , a pioneer in the treatment of drug-resistant fluid overload in liver disease, ...

Sequana Medical NV reported positive results from the second interim analysis of its POSEIDON pivotal study evaluating the Alfapump for the treatment of recurrent or refractory ascites due to liver ...

Swiss medical device startup Sequana Medical secured $23 million in Series C funds it will use to support global expansion of its products and begin clinical trials in the U.S. The company also said ...